Insightec Ltd. received U.S. FDA approval for use of its Exablate Neuro device to address severe motor symptoms in patients with Parkinson’s disease, offering a new option for patients who have not ...

HAIFA, Israel and WAUKESHA, Wisconsin, July 10, 2019 /PRNewswire/ -- GE Healthcare, a leader in medical technology and diagnostic and therapeutic imaging, and INSIGHTEC®, a global medical technology ...

Germany-based Insightec and Israel-based Siemens Healthineers entered into a strategic agreement to develop compatibility between Insightec’s Exablate Neuro device and Siemans’ clinical MRI systems.

The Food and Drug Administration approved the Exablate Neuro system as the first focused ultrasound device intended to treat essential tremor in patients who do not respond to conventional medication.

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min It uses novel focused ultrasound ...

The MarketWatch News Department was not involved in the creation of this content. New approval brings most advanced, efficient Exablate platform to Canada, expanding access to enhanced care for people ...

Insightec Ltd. broadened its CE mark approval for the Exablate Neuro, a focused ultrasound platform which treats essential tremors, to allow patients to have their second side treated. With some 60 ...

Insightec is helping some patients avoid brain surgery by using focused ultrasound to treat essential tremor in a noninvasive manner. Frank Vinluan Insightec's Exablate Neuro includes a helmet that ...

The MarketWatch News Department was not involved in the creation of this content. New approval brings most advanced, efficient Exablate platform to Canada, expanding access to enhanced care for people ...